Every patient success story we see today began with something simple—
An unanswered question.

Across decades of progress in our specialty, we’ve watched the support of research blossom into groundbreaking new understanding of disease, important new treatments for patients, and clinical innovations that move our specialty forward. Looking back on a tradition of discovery, we believe that for every disease we see in the practice of dermatology—there is a treatment or cure out there, awaiting development.

This is our extraordinary opportunity as a specialty—and this is our mission as the Dermatology Foundation.

Because of your generous support in 2017, the DF was able to make major investments in foundational work across the full breadth of our specialty—and the research we fund today will change patients’ lives tomorrow.

Even as we reflect on one of the most important years of our five-decade history, we know we’re still just getting started.
From the Trustees: A Year in Review

Every year, physicians and other investigators step forward with new ways to explore the most important research questions in our specialty. Every year, we step forward to invest in their work—helping to bridge the gap between research and the treatments that change patient care.

In 2017, we showed what is possible when we come together to move our specialty forward: significant support for wide-ranging research; promising developments and breakthroughs from past DF awardees; a new award to provide medical students belonging to an underrepresented minority group in medicine with a 6- to 12-week in-depth investigative experience—these are just a few highlights of what you will find in this year’s Annual Report. As we reflect on another year of extraordinary impact, we know that our shared work toward clinical innovations and new treatments remains as vital as ever.

We succeed together when we invest together.

In 2017, our members contributed $2.6 million to move our specialty forward. We remain the leading private funding source for skin disease research, and we celebrate the deep investments of our colleagues.

In-depth investigative experience—these are just a few highlights of what you will find in this year’s Annual Report. As we reflect on another year of extraordinary impact, we know that our shared work toward clinical innovations and new treatments remains as vital as ever.

Outside of our member contributions, we are grateful to our corporate and society supporters, who contributed a total of $1.77 million. We extend a special thanks to:

- Three Platinum Benefactors, who each contributed $200,000 or more: Caldeatra, Ortho Dermatologics, and Unilever
- Five additional Corporate Society members who gave $50,000 or more
- 15 total specialty societies who supported the DF, including the American Academy of Dermatology and the Women’s Dermatologic Society who each supported at $55,000

Investment drives innovation.

Powered by your committed investment, we were able to grant $2.6 million in funding for 58 projects with the potential to lead to clinical innovations and new treatments. In addition to our flagship research awards program, we also launched two promising new programs aimed at driving discovery in key areas.

We are proud to launch the Diversity Research Supplement Award, created to ensure that the field of dermatology and the specialty’s academic workforce reflects the world we live in. This important new award provides $5,000 for a medical student who identifies with an underrepresented minority (URM) group to participate in a full-time research plan. The award is available to recent recipients of DF career development awards and is used to support existing research for 6 to 12 weeks.

We are also excited to introduce the Stiefel Scholar Award, created as a result of a generous $1 million contribution from Charles and Daneen Stiefel to further research on the molecular and cellular basis of skin cancer. Providing $100,000 per year for three years, this award is intended to support three mid-career researchers.

Outside of our research awards, we celebrate the continued success of the DF’s Clinical Symposia—a highly regarded CME program for practicing dermatologists and a unique educational experience that attendees describe as informative and highly relevant for the practicing dermatologist. In 2017, the meeting reached capacity with 400 attendees, and featured 13 faculty presenters, eight of whom were former DF award recipients.

The work of the DF is carried forward by its many volunteers.

The DF would not have been able to accomplish what it did in 2017 without a base of volunteers who generously give their time, expertise and resources, including:

- The Board of Trustees and all our volunteers, who carried out the DF mission and devoted their time and energy to expanding its reach for the sake of physicians and patients
- The Medical & Scientific Committee and its panel, who set aside hours to review and rank 2018 applications for research funding
- Dr. Jim Ertle, the outgoing Chair of the Annenberg Circle Committee, along with members of the Annenberg Circle Committee—to the Annenberg Circle Campaign

A bright future for dermatology starts today.

New ideas, new knowledge, new treatments: all that is possible for tomorrow’s patients will be shaped by the decisions that we make now. If we continue to deepen our investment in research and support the next generation of dermatologists, the future of dermatology will be vibrant.
How We Fund Research

Who: A committee of world-class experts in all areas of dermatology

That is who convenes to form the DF’s Medical & Scientific Committee and make the most important recommendations about funding our specialty’s future.

What: Innovative ideas with the potential to change lives

That is what we fund, plain and simple. Our selection committee works from a set of standards: whether the applicant has a powerful, scientifically meritorious idea with the potential to transform patient care, and the training and institutional support to execute on it. We are committed to funding every applicant who meets that standard.

How: A proven process, modeled after the National Institutes of Health

That is how we review and rank every application, ensuring an equitable, science-based assessment of applications. The quality of our review process is evident in the success of our awardees, who go on to win NIH funding at far above-average rates.

What We Funded in 2017

Representing $2.6 million of awards for 58 unique research proposals, the funding breaks down as the following:

- 41 Career Development Awards
  - 4 Health Care/Public Policy
  - 5 Dermatologic Surgery
  - 8 Physician Scientists
  - 1 Science of Human Appearance
  - 8 Medical Dermatology
  - 3 Women’s Health
  - 8 Basic Research
  - 2 Dermatopathology Research
  - 2 Pediatric Dermatology

- 6 Dermatologist Investigator Research Fellowships
- 2 Research Grants
- 1 Charles & Daneen Stiefel Scholar Award in Skin Cancer

DF Research Award Funding

In 2017, we funded 58 research projects with the potential to shape the future of dermatology. These projects span the breadth of dermatology and represent exciting research frontiers in our field.
Dr. Ridky’s research began from the puzzle of why women, especially those who have previously been pregnant, have better melanoma outcomes than men. Reflecting on his experience in the clinic, he began with women’s observations about skin color darkening during pregnancy. He believed that identifying what stimulates melanocytes during pregnancies might expand their understanding of normal melanocyte biology. Dr. Ridky and his students connected a series of dots to discover that melanocytes (the cells involved in melanoma) are highly responsive to estrogen. He took this knowledge into the lab and observed that by activating a particular estrogen receptor (GPER) in mice, melanocytes become more differentiated and less proliferative—and thereby more susceptible to current immunotherapies. This important finding became the foundation for future research, and received DF funding in 2018 through the Stiefel Scholar Award.

Already Dr. Ridky’s research is making tremendous progress. When testing synthetic derivatives of GPER, Dr. Ridky has found a potential new class of therapeutics that, when combined with the modern anti-PD-1 immunotherapy, cures 50% of melanoma-bearing mice. For the mice who would otherwise succumb to tumor, these results are permanent. And when they successfully clear tumors, they also show development of durable immunity that protects them against subsequent tumors when they are reinjected with melanoma cells.

Embedded in Dr. Ridky’s research are exciting implications on human melanoma treatments.

The three-year Stiefel Scholar Award will provide Dr. Ridky the time and resources to continue his studies and move the therapy forward. For Dr. Ridky, “it provides needed research support at a critical time—as we work to expand on our recent findings and move GPER agonists to first-in-human trials for melanoma and other cancers.”
These are the people doing work today at the frontiers of our knowledge, broadening what we know and changing our approaches down the road. The Dermatology Foundation is proud to present its 2018 research award recipients, whose promising work spans the field of dermatology. Through our flagship Research Awards Program, the DF invested $2.59 million in 58 ideas with outstanding potential to advance patient care.

CHARLES & DANEEN STIEFEL SCHOLAR AWARD IN AUTOIMMUNE AND/OR CONNECTIVE TISSUE DISEASES

We are proud to offer a three-year research award made possible by a generous contribution from Charles and Daneen Stiefel—the 2018 Stiefel Scholar Award. This award is designed to support outstanding research committed to understanding the molecular and cellular basis of skin cancer (melanoma or non-melanoma) and/or its treatment. A generous mechanism of support providing $100,000 per year, this award is intended for mid-career investigators.

Todd W. Ridky, M.D., Ph.D.
University of Pennsylvania
Inhibiting Melanoma Via a Novel and Druggable GPCR Pathway

Women, especially previously-pregnant women, have more favorable melanoma outcomes than men do. The underlying reason has been unknown, but preliminary studies in our lab indicate that much of this protection results from a newly appreciated type of estrogen receptor, called GPER, that is found on melanocytes, the cells involved in melanoma. Activating these receptors in mice reprograms the tumor melanocytes toward a more "differentiated" state that makes them more vulnerable to current immunotherapies. Now we will test the ability of new estrogen derivatives that activate only GPER, and not the classic estrogen receptor, to make immunotherapies more effective and inhibit melanoma.

Career Development Awards

The bedrock of our work and the most competitive of our early career awards, career development awards (CDAs) support researchers at a critical juncture: when they are building the data and track record they need to win federal support for their research. The DF offers a variety of CDAs intended for projects with exceptional potential to contribute to the advancement of dermatology. Each provides $55,000 in annual salary support for up to three years.

PUBLIC HEALTH/CLINICAL CAREER DEVELOPMENT AWARD IN HEALTH CARE POLICY

Aaron M. Secrest, M.D., Ph.D., M.P.H.
University of Utah
Clinical Utility of Patient-Reported Outcomes in Dermatology

Electronic patient-reported outcomes (PROs) are collected from all patients in our large academic dermatology department to identify symptoms and inform clinical care. We will use these PROs to determine the real-world burden of skin diseases and the effectiveness of dermatology treatments at improving quality of life. These data will enhance dermatologists' provision of targeted and patient-centered care and counseling regarding skin disease and its treatment.

CLINICAL CAREER DEVELOPMENT AWARD IN DERMATOLOGIC SURGERY

Mary L. Stevenson, M.D.
New York University
Identification of Novel Risk Factors and Biomarkers for Poor Outcomes in Squamous Cell Carcinoma

While the majority of patients with cutaneous squamous cell carcinoma have excellent prognosis, a small subset of patients will develop metastasis. Identification of which tumors will behave aggressively is essential to improved prognostication guidelines and treatment algorithms. We aim to identify novel risk factors and biomarkers associated with tumors at risk for poor outcomes.
Patient-reported outcome measures (PROMs)—validated questionnaires developed from patient interviews—offer potential to improve patient health outcomes. No skin cancer-specific PROMs exist despite the knowledge gap in our understanding of how skin cancer affects patient quality of life. The aim of this study is to develop such an instrument using qualitative data from patient interviews that could be rapidly implemented in clinical care.

**CLINICAL CAREER DEVELOPMENT AWARD IN DERMATOLOGIC SURGERY**

Abigail Waldman, M.D., M.H.S.
Brigham and Women’s Hospital
Skin Cancer Life Impact and Functional Evaluation (LIFE)

Patient-reported outcome measures (PROMs)—validated questionnaires developed from patient interviews—offer potential to improve patient health outcomes. No skin cancer-specific PROMs exist despite the knowledge gap in our understanding of how skin cancer affects patient quality of life. The aim of this study is to develop such an instrument using qualitative data from patient interviews that could be rapidly implemented in clinical care.

**PHYSICIAN SCIENTIST CAREER DEVELOPMENT AWARD**

David Y. Chen, M.D., Ph.D.
Washington University
Epigenetic Regulation of Skin Homeostasis and Tumorigenesis

Increasing age and sun exposure, both major risk factors for developing skin cancer, are also associated with specific changes in DNA methylation in the skin. The goal of this study is to understand whether such changes in DNA methylation affect the ability of normal skin cells to become cancerous.

**MEDICAL DERMATOLOGY CAREER DEVELOPMENT AWARD**

Benjamin H. Kaffenberger, M.D.
Ohio State University
Prospective Categorization and Outcome Analysis of Cutaneous Drug Eruptions

Cutaneous adverse drug eruptions (drug rashes) are the most common skin disease in the hospital, but our current understanding of these reactions is extremely limited. This grant will support the development of new tools to differentiate the most common drug eruptions, while using national datasets to identify evidence for the importance of early and accurate recognition and intervention in these reactions.

**WOMEN’S HEALTH CAREER DEVELOPMENT AWARD**

Jillian M. Richmond, Ph.D.
University of Massachusetts
Targeting the CXCR3 Chemokine Axis in Cutaneous Lupus

Lupus is an autoimmune disease, a type of disease in which the body’s immune cells mistakenly attack the body’s own tissues. We will determine which molecular signals control the ability of these immune cells to get into the skin in lupus patients, with the hope of identifying new markers of disease and targets for treatment.
Atopic dermatitis (AD) involves complex interactions between host and environmental factors that are not fully understood. To better understand the underlying immune mechanisms of this skin disease, we will utilize a filaggrin-deficient mouse model to investigate the role of keratinocyte-derived IL-1α and its interaction with the skin microbiome in promoting disease-related inflammation. Our goal is to treat AD—and potentially other inflammatory skin disorders—more effectively.

Global rates of skin cancers and autoimmune diseases are rising and creating tremendous public health and economic burdens. Aire (autoimmune regulator), already known to influence autoimmunity, is also a key protein that promotes inflammation and nonmelanoma skin tumor growth. By determining molecular functions for Aire in skin, we will identify targets for new therapeutics that may serve as alternatives to laborious, expensive, and cosmetically disruptive surgery.

By delineating the role of the gene transcription factor VGLL3 in shaping the sex-specific responses to interferon, this study is designed to understand the molecular basis of a fundamental difference between men and women in immune regulation in skin. Clinically, it may provide a helpful target and pathway for preventing and treating autoimmune skin diseases, and also shed light on the sex-specific treatment of these diseases.

People who produce less of the enzyme A20 are more susceptible to psoriasis. Thus, A20 seems to protect people against this disease. We are doing experiments to understand which components of the A20 enzyme are most important for its protective function, and how it occurs. This will help us understand why certain people develop psoriasis and identify potential new ways to treat it.

Disruption of the epigenome (which includes the histone variant macroH2A) plays a critical role in a wide range of cancers, including melanoma. MacroH2A, which inhibits the metastatic potential of melanoma cell lines in the lab, is lost in invasive and metastatic human melanomas. Associating chromatin biology (the organizing framework) and dermatopathology, I will investigate the mechanisms through which macroH2A deficiency contributes to melanoma progression and metastasis.

The features, pathology, and clinical course of Spitz and dysplastic nevi in pediatric patients are poorly understood, particularly how they can lead to the development of melanoma. To identify relevant patterns and improve patient outcomes, I plan to study children and adolescents with these lesions over time, in addition to analyzing their risk factors, overall pattern of nevi, and sun exposure behaviors.

Establishing yourself as an independent investigator is one of the hardest things to do. My DF award enabled me to have a fighting chance.
Career Development Award Renewals

To receive a second or third year of funding, CDA recipients must provide evidence of substantial progress on their research projects and continued productivity in their academic and research careers. The following individuals have met the high standards for renewal of their awards.

<table>
<thead>
<tr>
<th>Award Category</th>
<th>Name</th>
<th>Institution</th>
<th>Project Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>PUBLIC HEALTH/CLINICAL CAREER DEVELOPMENT AWARD IN HEALTH CARE POLICY</td>
<td>Katrina E. Abuabara, M.D.</td>
<td>University of California, San Francisco</td>
<td>Eczema Epidemiology and Comorbidities</td>
</tr>
<tr>
<td></td>
<td>Arianne S. Kourosh, M.D., M.P.H.</td>
<td>Massachusetts General Hospital</td>
<td>Avatoras: A Telehealth Innovation to Address Access and Compliance Barriers for Chronic Skin Disease</td>
</tr>
<tr>
<td></td>
<td>Megan Noe, M.D., M.P.H.</td>
<td>University of Pennsylvania</td>
<td>Risk of Hospitalization for Pneumonia Adults with Chronic Skin Diseases</td>
</tr>
<tr>
<td>CLINICAL CAREER DEVELOPMENT AWARD IN DERMATOLOGIC SURGERY</td>
<td>Christian L. Baum, M.D.</td>
<td>Mayo Clinic, Rochester</td>
<td>Prognostic Risk Factors and Interventions for Patients with cSCC and CLINHIL</td>
</tr>
<tr>
<td></td>
<td>Jeremy R. Etzkorn, M.D.</td>
<td>University of Pennsylvania</td>
<td>Coherent Anti-Stokes Raman Spectroscopy for Basal Cell Carcinoma Diagnosis and Surgical Management</td>
</tr>
<tr>
<td></td>
<td>Emily Stamell Ruiz, M.D.</td>
<td>Brigham and Women’s Hospital</td>
<td>Skin Cancer Equity and Expenditure Analysis</td>
</tr>
<tr>
<td>PHYSICIAN SCIENTIST CAREER DEVELOPMENT AWARD</td>
<td>Marlys S. Fassett, M.D., Ph.D.</td>
<td>University of California, San Francisco</td>
<td>IL-31: Coupling Itch and Rash in Atopic Dermatitis</td>
</tr>
<tr>
<td></td>
<td>Jennifer G. Gill, M.D., Ph.D.</td>
<td>Southwestern Med. School Univ. of Texas</td>
<td>Transcriptional and Metabolic Adaptations of Melanoma Metastases</td>
</tr>
<tr>
<td></td>
<td>Tamia A. Harris-Tryon, M.D., Ph.D.</td>
<td>Southwestern Med. School Univ. of Texas</td>
<td>Determining the Function of Resistin-Like Molecule alpha (RELMα) in Cutaneous Host Defense</td>
</tr>
<tr>
<td></td>
<td>John C. Selby, M.D.</td>
<td>University of Iowa</td>
<td>The Mechanobiological Paradigm of Keratinocyte Re-Epithelialization: Effects of Matrix Stiffness</td>
</tr>
<tr>
<td></td>
<td>Cory L. Simpson, M.D., Ph.D.</td>
<td>University of Pennsylvania</td>
<td>Mechanism of Selective Autophagy in Epidermal Differentiation and Homeostasis</td>
</tr>
<tr>
<td>SCIENCE OF HUMAN APPEARANCE CAREER DEVELOPMENT AWARD</td>
<td>Ka Wai Mok, Ph.D.</td>
<td>Icahn School of Medicine at Mount Sinai</td>
<td>Identifying the Key Niche Signals for Hair Follicle Formation</td>
</tr>
<tr>
<td>MEDICAL DERMATOLOGY CAREER DEVELOPMENT AWARD</td>
<td>Joshua Arbesman, M.D.</td>
<td>Case Western Reserve University</td>
<td>Identifying Novel Preventative Approaches in Melanoma Using Genetics of Very High-Risk Families</td>
</tr>
<tr>
<td></td>
<td>Zelma C. Chiesa-Fuxench, M.D.</td>
<td>University of Pennsylvania</td>
<td>Atopic Dermatitis: Expanding Our Understanding of Complex Disease in the Hispanic Population</td>
</tr>
<tr>
<td></td>
<td>Hadar Lev-Tov, M.D., M.A.S.</td>
<td>University of Miami</td>
<td>Understanding First Venous Leg Ulcers in People with Venous Insufficiency</td>
</tr>
<tr>
<td></td>
<td>Alina Markova, M.D.</td>
<td>Cornell University</td>
<td>Epidemiology and Mechanisms of Dermatologic Disease in Hospitalized Patients with Cancer</td>
</tr>
<tr>
<td></td>
<td>Haley B. Naik, M.D.</td>
<td>University of California, San Francisco</td>
<td>Investigating the Role of the Skin Microbiome in Hidradenitis Suppurativa</td>
</tr>
<tr>
<td>WOMEN’S HEALTH CAREER DEVELOPMENT AWARD</td>
<td>Mei Li, Ph.D.</td>
<td>Brown University</td>
<td>Clinical and Genetic Epidemiology of Atypical Nevi</td>
</tr>
<tr>
<td></td>
<td>Zelma C. Chiesa-Fuxench, M.D.</td>
<td>University of Pennsylvania</td>
<td>Exploiting Mechanisms of Drug Addiction to Suppress MAPK Resistance in Melanoma</td>
</tr>
<tr>
<td></td>
<td>Bethany E. Perez-White, Ph.D.</td>
<td>Northeastern University</td>
<td>Breaking Down Barriers: Defining the Role of EphA2 in Building Epidermal Tight Junctions</td>
</tr>
<tr>
<td></td>
<td>Roberto R. Ricardo-Gonzalez, M.D., Ph.D.</td>
<td>University of California, San Francisco</td>
<td>Study of Innate Lymphoid Cells Type 2 in the Skin</td>
</tr>
<tr>
<td>DERMATOPATHOLOGY RESEARCH CAREER DEVELOPMENT AWARD</td>
<td>Leslie A. Castelo-Soccio, M.D., Ph.D.</td>
<td>University of California, Davis</td>
<td>Molecular Stains of Inherited and Sporadic Melanocytic Nevi</td>
</tr>
<tr>
<td></td>
<td>Maija Kiuru, M.D., Ph.D.</td>
<td>University of California, San Francisco</td>
<td>Study of Innate Lymphoid Cells Type 2 in the Skin</td>
</tr>
<tr>
<td>PEDIATRIC DERMATOLOGY CAREER DEVELOPMENT AWARD</td>
<td>Janet D. Odell, M.D., Ph.D.</td>
<td>Yale University</td>
<td>Functional Analysis of Dendritic Cells and Development of a Humanized Mouse Model of Scleroderma</td>
</tr>
</tbody>
</table>
In supporting researchers on the path to clinical innovation, the earliest investments can be the most powerful. Our fellowships support individuals who have recently completed their dermatology residency training and are embarking on careers in academic research. Each provides a one-year salary stipend of $30,000.

Christopher S. Crowley, M.D.
University of California, San Diego
Investigation of the Role of the Volume Regulated Anion Channels (VRACs) in Keratinocyte Biology

The pathophysiology of Hailey-Hailey disease is poorly understood. A novel possible mechanism relates the elevated cytosolic [Ca2+] found in Hailey-Hailey disease to the activity of the recently characterized volume-regulated anion channels (VRACs) that are in the outer cell membrane and regulate cell volume. We propose to interrogate the role of VRACs in Hailey-Hailey disease and perform relevant structural studies using cryoelectron microscopy.

Marianna Freudzon, M.D.
Yale University
Understanding the Role of GILT in Malaria Transmission in Skin

Understanding malaria transmission at the port of entry in the skin is key to identifying effective targets for vaccine development. We will use innovative imaging technology to examine parasite motility and blood vessel invasion in the dermis at the site of the mosquito bite, focusing on the role of a key mosquito saliva protein, GILT, that binds to the parasite.

Melissa A. Kinnebrew, M.D., Ph.D.
University of California, San Francisco
Defining the Mechanisms of Thermoregulation in the Skin

Subcutaneous fat not only provides the skin with structural support and nutrient storage, it is also crucial for hair follicle cycling, wound healing, systemic metabolism, and thermoregulation. We will investigate the mechanisms by which subcutaneous fat responds to cold temperatures to maintain skin barrier function. These studies may reveal therapeutic targets that can be exploited to treat chronic ulcers, lipodystrophy, and fibrosing skin disease.

Rie Takahashi, M.D., Ph.D.
University of California, Los Angeles
Metabolic Landscape of Human Cutaneous Squamous Cell Carcinomas

We aim to improve understanding of key metabolic pathways that drive cutaneous squamous cell carcinomas (SCCs) in patients. In some tumors, stem cells can proliferate to promote tumor growth and, similar to proliferative cancer cells, utilize glycolysis to do so. We propose that the metabolism of SCCs is linked to their cell of origin, and that disruption of glycolysis may inhibit SCC progression.

Margaret Wat, M.D., Ph.D.
Case Western Reserve University
Genetic and Molecular Mechanisms of Cutaneous T-Cell Lymphoma

Cutaneous T-cell lymphomas (CTCL) are the most common type of lymphomas that occur in the skin, but how they form and progress is not well understood. We will examine genetic changes in patients with early-onset CTCL to obtain insight into early triggers of this lymphoma. These results can likely improve understanding of CTCL once it has developed.

Sarah Whitley, M.D., Ph.D.
University of Pittsburgh
IL-23 Regulates Cutaneous Resident Memory T Cell Development

In addition to a physical barrier, the skin is a front line where immune cells identify and combat foreign pathogens. CD4 T cells (TCs), a key immune cell, become long-lived memory TCs and endow protection from repeat pathogen challenges. This project will characterize the developmental and maintenance requirements of a newly characterized subset of IL-17- producing skin-resident memory TCs (TRM17) to provide a scientific foundation for their potential therapeutic manipulation.
Grants

Each year, the DF funds research grants to support basic science, and medical and surgical studies with the potential to benefit the entire dermatologic community. These grants provide $20,000 to support the non-salary elements of a research project.

Duncan Hieu M. Dam, Ph.D.
Northwestern University
Role of Scavenger Receptors in Modulation of Toll-like Receptors Activation in Viral Skin Infections

Viral infections cause a range of high-impact human cutaneous diseases. Invading pathogens are recognized by the innate immune system’s toll-like receptors (TLRs), the skin’s first line of defense. Scavenger receptors (SRs) help regulate TLR activation in animals, but virtually nothing is known about SRs in human skin. We will study them comprehensively in multiple human skin models. Results could lead to new therapeutic strategies against viruses.

William W. Huang, M.D., M.P.H.
Wake Forest University
Developing the Pyoderma Gangrenosum Area and Severity Index (PGASI): An Outcome Instrument for PG

Pyoderma gangrenosum (PG) is a rare, severe, ulcerating, and painful skin disease. A lack of validated tools to determine the impact of therapy on disease activity has resulted in the absence of a uniform therapeutic standard. This project will develop a standardized measurement instrument for PG—the PG Area and Severity Index (PGASI)—that can be used in future clinical trials.

Diversity Research Supplement Award

Achieving a workforce that mirrors every community is an important long-term challenge that can be advanced by attracting more medical students from underserved populations to the specialty. This year, the DF stepped up to this important challenge by introducing the Diversity Research Supplement Award. This award supports a medical student—specifically one belonging to an underserved minority group in medicine—as they supplement the work of a recent DF Career Development Award recipient through a 6- to 12-week in-depth investigative experience in dermatology. The DF was proud to support eight Diversity Research Supplement Awards for 2018 and is honored to contribute in this meaningful way to improving diversity in the specialty.

Emma Guttman, M.D., Ph.D.
Icahn School of Medicine at Mt. Sinai
Difference in the Evaluation, Treatment and Comorbidities of Psoriasis in Patients with Skin of Color

There are significant differences in psoriasis patients between those with skin of color and Caucasians. More pigmented skin may make PASI scoring less accurate, and they may receive more combination therapy. The medical student will help to study severity evaluation in patients with skin types 5 and 6, validate a PASI scoring system, and mine two large databases to characterize treatment and comorbidity differences.

Stephanie von Caiky-Sessoms, Medical Student
Icahn School of Medicine at Mt. Sinai

Jennifer T. Huang, M.D.
Boston Children’s Hospital
Examining Racial Disparities in Dermatologic Care of Children with Cancer

Fiatsogbe S. Dzuali, Medical Student
Harvard University

Minority adults in the U.S. typically have markedly inadequate access to dermatologic care vis-à-vis Caucasians. Such data are lacking within the pediatric oncology population despite their high burden of dermatologic disease following cancer treatment. Using our demonstration that pediatric dermatologists can improve diagnostic accuracy and treatment for children with oncologic conditions, the medical student will identify the variables relevant to racial disparities and propose care improvement strategies.
P1: Eleni Linos, M.D., M.P.H., Dr.PH
University of California, San Francisco
Skin Cancer Prevention in Sexual Minorities

The p16INK4A tumor suppressor gene is frequently inactivated in skin cancers, typically through methylation of its promoter rather than by deletion or mutation. Such epigenetic changes have the potential to be reversed—i.e., DNA demethylation, restoring gene expression. The medical student will participate in developing novel epigenome editing tools to induce DNA demethylation, to upregulate this tumor suppressor gene and inhibit skin cancer.

P2: Thomas H. Leung, M.D., Ph.D.
University of Pennsylvania
Understanding the Pathogenesis of Neutrophilic Dermatoses

While acute febrile neutrophilic dermatosis (Sweet’s syndrome) is clinically well-characterized, little is known about the underlying molecular and cellular programs. Using prospectively collected human tissue, the medical student will help to assess the clonality of infiltrating neutrophils to determine a neoplastic or reactive process, and perform transcriptome analysis of isolated neutrophils to identify altered gene pathways.

P3: Janis M. Taube, M.D., M.Sc.
Johns Hopkins University
Characterizing Cell Type-Specific PD-1 and PD-L1 Expression in Melanoma

Therapeutic blockade of the PD-1/PD-L1 immune checkpoint pathway generates durable melanoma remissions in a patient subset. PD-L1 expression on melanoma cells as detected by immunohistochemistry is only suggestive of outcome. To identify predictive patterns, we are using multiplex immunofluorescence to determine human cell types expressing PD1/PD-L1, expression levels, and cellular interactions. The medical student will contribute image analysis and statistically process data.
Clinical Symposia Profile

An update on DF’s annual CME meeting that convenes our specialty’s best—to ensure our brightest future.

Each year, the Dermatology Foundation is proud to offer the Clinical Symposia, one of the specialty’s most highly-regarded professional educational conferences. Provocative presentations and engaging break-out sessions convey the latest and most relevant research findings, demonstrate how we can put them into practice, and bring physicians and researchers into dialogue in a uniquely intimate conference setting.

Held in January in Naples, FL., the 2018 program drew nearly 400 physicians who came ready to learn and interact with some of the specialty’s leading experts. Over three days, the Symposia’s 13 distinguished faculty experts—six of whom are prior DF award recipients—explored topics ranging from dermatologic surgery and emerging diseases to health policy, patient interactions, and practice satisfaction.

The Yale School of Medicine accredited the Clinical Symposia for 17.5 AMA PPR Category 1 Credits®. The DF extends its thanks and praise to Program Co-Chairs Janet A. Fairley, M.D. and Jack S. Resneck, Jr., M.D. and the distinguished faculty members who are responsible for the success of this year’s exciting set of talks. The DF also gratefully acknowledges the corporate donors who make this important event possible.

2018 RESIDENT PROGRAM

We are grateful to Unilever for providing an educational grant for the Clinical Symposia Resident Program, enabling 50 residents to attend the Clinical Symposia.

2018 CLINICAL SYMPOSIA CORPORATE SUPPORTERS

The Clinical Symposia would not have been possible without the commitment of our Corporate Supporters.

Diamond Supporters
Galderma Laboratories, LP
Ortho Dermatologics, a wholly owned subsidiary of Bausch Health Companies Inc.

Emerald Supporters
AlvVii
Sun Dermatology

Sapphire Supporters
Amgen Inc.
Daavlin

 Truly the best derm meeting I have ever been to.

"
Industry and Specialty Partners: Corporate Honor Society

Corporate Honor Society

The DF Trustees recognize Corporate Honor Society members for sharing in the belief that young researchers hold the potential to shape our specialty’s future and improve patients’ lives everywhere.

The members of our Corporate Honor Society have contributed $50,000 or more.

<table>
<thead>
<tr>
<th>PLATINUM BENEFACtor ($200,000 OR MORE)</th>
<th>SILVER BENEFACtor ($50,000 OR MORE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Galderma Laboratories, L.P.</td>
<td>AbbVie</td>
</tr>
<tr>
<td>Unilever</td>
<td>Amgen Inc.</td>
</tr>
<tr>
<td>Ortho Dermatologics</td>
<td>Lilly USA, LLC</td>
</tr>
<tr>
<td></td>
<td>Novartis</td>
</tr>
<tr>
<td></td>
<td>Sun Dermatology</td>
</tr>
</tbody>
</table>

Society Partners

These outstanding national dermatologic societies are among the Foundation’s most important partners. We express our deepest appreciation for supporting the DF Research Awards Program.

American Academy of Dermatology ($55,000)
Women’s Dermatologic Society ($55,000)

Benefactors, Patrons, and Sponsors

The DF gratefully acknowledges the support of the following corporations and societies for their commitment to progress in the specialty.

DISTINGUISHED BENEFACtor ($25,000 OR MORE)
Daavlin
Celgene Corporation
Pfizer, Inc

BENEFACtor, LEVEL III ($10,000 OR MORE)
Cutenea Life Sciences
Dermira
Promius Pharma, LLC

BENEFACtor, LEVEL II ($5,000 OR MORE)
Colostrum
Encore Dermatology
Iowa Dermatological Society
Myriad Genetics, Inc.

BENEFACtor, LEVEL I ($2,500 OR MORE)
Claire Marie Foundation
Philadelphia Dermatological Society
Kentucky Dermatological Society
San Antonio Dermatological Society
Wisconsin Dermatological Society

PATRON ($1,000 OR MORE)
Actelion Pharmaceuticals US, Inc.
Dermatological Society of New Jersey
Buffalo Rochester Dermatology Society
Alabama Dermatological Society
Herbert M. & Naomi R. Loewitt Family Charitable Trust
Maryland Dermatologic Society
Memphis Dermatology Society
Pittsburgh Academy of Dermatology
Richmond Dermatology Society
Oklahoma State Dermatology and Dermatologic Surgery Society
A Gift of $100,000

We are profoundly grateful to members of the Thomas B. Fitzpatrick Legacy Fund for their vision, generosity, and decision to ensure that we are investing in the research that will change what is possible for dermatologists.

The members of the Thomas B. Fitzpatrick Legacy Fund provide a one-time gift of $100,000 or more:

Ren A. Ammott, M.D.
Susan V. Bernhard, M.D.
Gordon J. Doe, Pharm.D.
Harley A. Haynes, M.D.
Stuart R. Kean, M.D.
James J. Leyden, M.D.
Robert L. Reschel, M.D.
Jenah Shcheri
Charles W. Stiefel
Eugene J. Van Scott, M.D.
Ruey J. Yu, Ph.D., O.M.D.
Anonymous Donor
Ruey J. Yu, Ph.D., O.M.D.
Eugene J. Van Scott, M.D.
Charles W. Stiefel
Jonah Shacknai
Robert L. Reschel, M.D.
James J. Leyden, M.D.
Stuart R. L. Lebowitz, M.D.
Harley A. Haynes, M.D.
Gordon J. Dow, Pharm.D.
Susan V. Bershad, M.D.
Rex A. Amonette, M.D.

Deferred Giving

The Board of Trustees expresses its deep gratitude to the Charles A. Oclassen Charitable Fund for its generous support.

A Gift of $100,000

We are profoundly grateful to members of the Thomas B. Fitzpatrick Legacy Fund for their vision, generosity, and decision to ensure that we are investing in the research that will change what is possible for dermatologists.

The members of the Thomas B. Fitzpatrick Legacy Fund provide a one-time gift of $100,000 or more:

Ren A. Ammott, M.D.
Susan V. Bernhard, M.D.
Gordon J. Doe, Pharm.D.
Harley A. Haynes, M.D.
Stuart R. Kean, M.D.
James J. Leyden, M.D.
Robert L. Reschel, M.D.
Jenah Shcheri
Charles W. Stiefel
Eugene J. Van Scott, M.D.
Ruey J. Yu, Ph.D., O.M.D.
Anonymous Donor
Ruey J. Yu, Ph.D., O.M.D.
Eugene J. Van Scott, M.D.
Charles W. Stiefel
Jonah Shacknai
Robert L. Reschel, M.D.
James J. Leyden, M.D.
Stuart R. L. Lebowitz, M.D.
Harley A. Haynes, M.D.
Gordon J. Dow, Pharm.D.
Susan V. Bershad, M.D.
Rex A. Amonette, M.D.

Deferred Giving

The Board of Trustees expresses its deep gratitude to the Charles A. Oclassen Charitable Fund for its generous support.

A Gift of $100,000

We are profoundly grateful to members of the Thomas B. Fitzpatrick Legacy Fund for their vision, generosity, and decision to ensure that we are investing in the research that will change what is possible for dermatologists.

The members of the Thomas B. Fitzpatrick Legacy Fund provide a one-time gift of $100,000 or more:

Ren A. Ammott, M.D.
Susan V. Bernhard, M.D.
Gordon J. Doe, Pharm.D.
Harley A. Haynes, M.D.
Stuart R. Kean, M.D.
James J. Leyden, M.D.
Robert L. Reschel, M.D.
Jenah Shcheri
Charles W. Stiefel
Eugene J. Van Scott, M.D.
Ruey J. Yu, Ph.D., O.M.D.
Anonymous Donor
Ruey J. Yu, Ph.D., O.M.D.
Eugene J. Van Scott, M.D.
Charles W. Stiefel
Jonah Shacknai
Robert L. Reschel, M.D.
James J. Leyden, M.D.
Stuart R. L. Lebowitz, M.D.
Harley A. Haynes, M.D.
Gordon J. Dow, Pharm.D.
Susan V. Bershad, M.D.
Rex A. Amonette, M.D.

Deferred Giving

The Board of Trustees expresses its deep gratitude to the Charles A. Oclassen Charitable Fund for its generous support.

A Gift of $100,000

We are profoundly grateful to members of the Thomas B. Fitzpatrick Legacy Fund for their vision, generosity, and decision to ensure that we are investing in the research that will change what is possible for dermatologists.

The members of the Thomas B. Fitzpatrick Legacy Fund provide a one-time gift of $100,000 or more:

Ren A. Ammott, M.D.
Susan V. Bernhard, M.D.
Gordon J. Doe, Pharm.D.
Harley A. Haynes, M.D.
Stuart R. Kean, M.D.
James J. Leyden, M.D.
Robert L. Reschel, M.D.
Jenah Shcheri
Charles W. Stiefel
Eugene J. Van Scott, M.D.
Ruey J. Yu, Ph.D., O.M.D.
Anonymous Donor
Ruey J. Yu, Ph.D., O.M.D.
Eugene J. Van Scott, M.D.
Charles W. Stiefel
Jonah Shacknai
Robert L. Reschel, M.D.
James J. Leyden, M.D.
Stuart R. L. Lebowitz, M.D.
Harley A. Haynes, M.D.
Gordon J. Dow, Pharm.D.
Susan V. Bershad, M.D.
Rex A. Amonette, M.D.

Deferred Giving

The Board of Trustees expresses its deep gratitude to the Charles A. Oclassen Charitable Fund for its generous support.

A Gift of $100,000

We are profoundly grateful to members of the Thomas B. Fitzpatrick Legacy Fund for their vision, generosity, and decision to ensure that we are investing in the research that will change what is possible for dermatologists.

The members of the Thomas B. Fitzpatrick Legacy Fund provide a one-time gift of $100,000 or more:

Ren A. Ammott, M.D.
Susan V. Bernhard, M.D.
Gordon J. Doe, Pharm.D.
Harley A. Haynes, M.D.
Stuart R. Kean, M.D.
James J. Leyden, M.D.
Robert L. Reschel, M.D.
Jenah Shcheri
Charles W. Stiefel
Eugene J. Van Scott, M.D.
Ruey J. Yu, Ph.D., O.M.D.
Anonymous Donor
Ruey J. Yu, Ph.D., O.M.D.
Eugene J. Van Scott, M.D.
Charles W. Stiefel
Jonah Shacknai
Robert L. Reschel, M.D.
James J. Leyden, M.D.
Stuart R. L. Lebowitz, M.D.
Harley A. Haynes, M.D.
Gordon J. Dow, Pharm.D.
Susan V. Bershad, M.D.
Rex A. Amonette, M.D.

Deferred Giving

The Board of Trustees expresses its deep gratitude to the Charles A. Oclassen Charitable Fund for its generous support.

A Gift of $100,000

We are profoundly grateful to members of the Thomas B. Fitzpatrick Legacy Fund for their vision, generosity, and decision to ensure that we are investing in the research that will change what is possible for dermatologists.

The members of the Thomas B. Fitzpatrick Legacy Fund provide a one-time gift of $100,000 or more:

Ren A. Ammott, M.D.
Susan V. Bernhard, M.D.
Gordon J. Doe, Pharm.D.
Harley A. Haynes, M.D.
Stuart R. Kean, M.D.
James J. Leyden, M.D.
Robert L. Reschel, M.D.
Jenah Shcheri
Charles W. Stiefel
Eugene J. Van Scott, M.D.
Ruey J. Yu, Ph.D., O.M.D.
Anonymous Donor
Ruey J. Yu, Ph.D., O.M.D.
Eugene J. Van Scott, M.D.
Charles W. Stiefel
Jonah Shacknai
Robert L. Reschel, M.D.
James J. Leyden, M.D.
Stuart R. L. Lebowitz, M.D.
Harley A. Haynes, M.D.
Gordon J. Dow, Pharm.D.
Susan V. Bershad, M.D.
Rex A. Amonette, M.D.

Deferred Giving

The Board of Trustees expresses its deep gratitude to the Charles A. Oclassen Charitable Fund for its generous support.

A Gift of $100,000

We are profoundly grateful to members of the Thomas B. Fitzpatrick Legacy Fund for their vision, generosity, and decision to ensure that we are investing in the research that will change what is possible for dermatologists.

The members of the Thomas B. Fitzpatrick Legacy Fund provide a one-time gift of $100,000 or more:

Ren A. Ammott, M.D.
Susan V. Bernhard, M.D.
Gordon J. Doe, Pharm.D.
Harley A. Haynes, M.D.
Stuart R. Kean, M.D.
James J. Leyden, M.D.
Robert L. Reschel, M.D.
Jenah Shcheri
Charles W. Stiefel
Eugene J. Van Scott, M.D.
Ruey J. Yu, Ph.D., O.M.D.
Anonymous Donor
Ruey J. Yu, Ph.D., O.M.D.
Eugene J. Van Scott, M.D.
Charles W. Stiefel
Jonah Shacknai
Robert L. Reschel, M.D.
James J. Leyden, M.D.
Stuart R. L. Lebowitz, M.D.
Harley A. Haynes, M.D.
Gordon J. Dow, Pharm.D.
Susan V. Bershad, M.D.
Rex A. Amonette, M.D.

Deferred Giving

The Board of Trustees expresses its deep gratitude to the Charles A. Oclassen Charitable Fund for its generous support.
SHAPING THE FUTURE OF DERMATOLOGY

Annenberg Circle

Contribute to the future of dermatology research and education by joining the Annenberg Circle—a select group of benefactors committed to advancing the field of dermatology. Members are key to propelling our vision into reality.

Annenberg Circle Members

Annenberg Circle members pledge $25,000 or more. Gifts of this magnitude make an enormous difference in accelerating the progress of dermatological research and in sustaining the early careers of some of the country's most promising researchers.

ALABAMA

James E. Elder, M.D.
Barry E. Eeles, M.D.
Christopher R. Harris, M.D.
Elisabeth Sanders Jacobsen, M.D.
J. Alan Long, M.D.
Amy Markert Morris, M.D.
Lori E. Babey, Jr., M.D.
Laura McNally Tianhui, M.D.
Julian M. Thomas, M.D.
George G. Tidwell, M.D.

ARIZONA

Bill O. Hayes, M.D.
Paul W. Becker, M.D.
Paul E. English, M.D.
Marc I. Epstein, D.O.
David N. Flageolet, M.D.
John M. Hamilton, M.D.
Michael J. Huetter, M.D.
Ray S. Rogers, III, M.D.

CALIFORNIA

John R. Epstein, M.D.
Kathryn A. Fiddick, M.D.
Richard E. Forzycki, M.D.
Michael J. Franklin, M.D.
Glenda E. Frink, M.D.
John K. Gnae, M.D.
Michael F. Goldman, M.D.
Paul E. Grimes, M.D.
Karly J. Grohman, M.D.
Robert D. Grossberg, M.D.
Donald Richard Greene, M.D.
David J. Jeffel, M.D.
Jennifer M. Kneubuhl, M.D.
Frank D. Mann, M.D.
Barry J. Richman, M.D.
Lauren A. Sibbald, M.D., Ph.D.
Robert R. Tugwell, M.D.

CONNECTICUT

Jose L. Bologna, M.D.
Irvin M. Buxbaum, M.D.
Kevin M. Dietle, M.D.
Robert J. Friedman, M.D.
Michael Giordano, M.D.
Robert D. Grossberg, M.D.
Donald Richard Greene, M.D.
David J. Jeffel, M.D.
Jennifer M. Kneubuhl, M.D.
Frank D. Mann, M.D.
Barry J. Richman, M.D.
Lauren A. Sibbald, M.D., Ph.D.
Robert R. Tugwell, M.D.

DELAWARE

Michael C. Stickler, M.D.
Marguerite D. Thore, M.D.

DISTRICT OF COLUMBIA

Tina S. Ahn, M.D.
Martin Strauss, III, M.D.
Cheryl M. Burgess, M.D.
Martin B. Brown, M.D.
Maryvpay, S. Martin, M.D.
Kevin B. Nash, III, M.D.
Alan M. Shapira, M.D.
Karen A. Tollefsen, M.D.
Michael L. Tollefsen, M.D.
John R. Z下午, M.D.

FLORIDA

Leslie Remazone, M.D.
Barry R. Reuc, M.D.
James C. Cummins, M.D.
Judith R. Crosson, M.D.
Asa M. Dunn, M.D.
Craig J. Ensell, M.D.
Anna F. Palazzolo, M.D.
Michael J. Feinstein, M.D.
Philip Rose, M.D.

GEORGIA

Jack D. Althea, III, M.D.
Charity A. Bayles, M.D.
Robert D. Brown, M.D.
Lynne A. Carter, M.D.
Brian J. Cline, M.D.
Matthew E. Kohler, M.D.
James Lakhi, M.D.
Anna E. Lachman, M.D.
Michael E. Cohen, M.D.
Patricia Farmer, M.D.
Leonard E. Gately, III, M.D.
Dennis B. Boyle Hooper, M.D.
Janice D. Hopkins, M.D.
Catherine J. Johnson, M.D.
John J. Jones, M.D.
Elizabeth Bory brigade, M.D.
Mary P. Lopez, M.D.
Thomas N. Nicola, Jr., M.D.
Mary P. Nguyen, M.D.

HAWAI'I

Ted S. Sih, M.D.
Robert S. Hayashi, M.D.

IDAHO

Ryan Babb, M.D.
Alan D. Olmstead, M.D.
Ryan S. Owsley, M.D.
Carl R. Wellstein, M.D.

ILLINOIS

Jeffrey A. Alcrast, M.D.
Thomas W. Andrews, M.D.
Ronald L. Moy, M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
Robert G. Carney, Jr., M.D.
Timothy S. Brown, M.D.
Peter J. Chang, M.D.
Charles W. Brown, Jr., M.D.
Tracy C. Brown, M.D.
MONTANA
Jeffry A. Golden, M.D.
Jilliana Hicks, M.D.
NEBRASKA
Suzanne W. Bredlisch, M.D.
David N. Kingery, M.D.
Joel Schoengen, M.D.
David J. Watts, M.D.
NEVADA
James Q. Del Rossio, D.O.
NEW JERSEY
Susan Y. Besorah, M.D.
David E. Cohen, M.D., M.P.H.
Garin L. Groisser, M.D.
William F. Gouldish, M.D.
Sharon A. Gablin, M.D.
David J. Goldberg, M.D.
David S. Gordon, M.D.
Vivian C. Hoyman, M.D.
William O. Ja, M.D.
Carrie L. Korsak, M.D.
Kent S. Sutter, M.D.
NEW MEXICO
Joel B. Bankoff, M.D.
Andrew S. Mandel, M.D.
NEW YORK
Andrew A. Amin, M.D., M.P.H.
Douglas G. Atteck, M.D.
Diane B. Saron, M.D.
David E. Reis, M.D.
Videk J. Brooks, M.D.
Marc D. Brown, M.D.
Karen E. Burke, M.D., Ph.D.
J. Andrew Cordin, M.D.
Judee Tek Copley, M.D.
Steven R. Cohen, M.D., M.P.H.
Helen Tenenbaum, M.D.
Linda E. Franklin, M.D.
Francesca J. Fico, M.D.
Roy G. Gerber, M.D.
Richard D. Graunstein, M.D.
N. Patrick Harperman, M.D.
Carol L. Haag, M.D.
Marie-Louise Johnson, M.D., Ph.D.
Albert M. Leikwim, M.D.
Tamaray D. Mattison, M.D.
Grace H. Pak, M.D.
Donald Rudikoff, M.D.
Neil S. Sadick, M.D.
Farranaza H. Sama, M.D.
Richard E. Sauty, M.D.
David M. Segel, M.D.
Robert R. Walber, M.D.
Patricia S. Winker, M.D.
NORTH CAROLINA
Matthew H. Bydonov, M.D.
Robert A. Briggaman, M.D.
Craig B. Nuckalt, M.D.
Marc R. Caravell, M.D.
Steven R. Fialkoff, M.D., Ph.D.
Lori S. Goldsmith, M.D.
Gloria F. Graham, M.D.
Barry L. Green, M.D.
Delia C. Liao, M.D.
Frederick A. Sopris, III, M.D.
Eli A. Olson, M.D.
M. Joyce Rico, M.D.
Stuart Talton, M.D.
Jon C. Tortonese, M.D.
W. Harrison Turner, III, M.D.
NORTH DAKOTA
Ben M. Tran, M.D.
OHIO
Brent M. Goldstein, M.D.
Charles L. Hueste, M.D.
Lee C. Kline, M.D.
Neil J. Kramer, M.D., Ph.D.
David J. Kobus, M.D., Ph.D.
Stephen R. Leitch, M.D.
Gary F. Lipshon, M.D.
Michael G. Mancuso, M.D.
John C. Mead, M.D.
Eller M. Shives, M.D., M.P.H.
Diniy F. Shihab, M.D.
Nancy J. Paj, M.D.
Jennifer M. Rigby, M.D.
Shahid M. Wilcox, D.O.
OKLAHOMA
John R. Anley, M.D.
Raymond L. Cornish, Jr., M.D.
OREGON
Dean R. Baker, M.D.
Walter G. Donnen, M.D.
Sancy A. Leachman, M.D., Ph.D.
Edgar Maryanov, Jr., M.D.
Robert T. Matheson, M.D.
John E. Ranken, M.D.
Gregory C. Rumback, M.D.
Stephen N. Snow, M.D.
Neil A. Swanson, M.D.
Douglas K. Zirker, M.D.
SOUTH CAROLINA
Katherine R. Haney, M.D.
Jack L. Leek, Jr., M.D.
Christopher M. Paterson, M.D.
TENNESSEE
Roch A. Armarino, M.D.
John J. Atkin, M.D.
Lawrence L. Buddold, M.D.
Dan A. Dunaway, M.D.
Martin E. Elley, M.D.
Robert F. Massacca, M.D.
J. Harvey Gelfand, M.D.
Michael H. Gold, M.D.
Jonathan N. Grubkin, M.D.
Barbara A. Kadow, M.D.
John D. Haber, M.D.
Julie M. Pena, M.D.
James E. Turner, M.D., Ph.D.
TEXAS
Lawrence L. Anderson, M.D.
Phillip R. Bannual, M.D.
Sonia B. Rana, M.D.
Stuart R. Lessin, M.D.
Vickey A. Martin, M.D.
Mary C. Martini, M.D.
Barbara M. Mathes, M.D.
O. Fred MILLER, M.D., Ph.D.
Stephan M. Parcell, D.O.
Francesca Ringpfeil, M.D.
Alan R. Rook, M.D.
Robert E. Roschel, M.D.
Stuart Daniel Shanler, M.D.
William K. Sherwin, M.D., Ph.D.
Sancy A. Leethner, M.D.
Karen A. Lead, M.D.
M. Gayle Mulleran, M.D.
Denise E. Newton, III, M.D.
Jack L. Sisson, III, M.D.
William T. Parsons, M.D.
R. Todd Hert, M.D.
William Perone, M.D.
Sharon S. Ramee, M.D.
William M. Ramadott, M.D.
Ronald P. Ray, M.D.
Carl R. Reinzinger, M.D.
Richard N. Rudnicki, M.D.
Danny D. Schneidler, M.D.
Alan K. Silverman, M.D.
Cheyne L. Johnson, M.D.
R. Stan Taylor, M.D.
Bryan L. Voorhees, M.D.
Stephen K. Tryning, M.D., Ph.D.
Trace W. Vandergeff, M.D.
Pamela J. Vogel, M.D.
Mark R. Weisman, M.D.
Peyi S. Zeikus, M.D.
UTAH
D. Edgar Allen, M.D.
Armand R. Brown, M.D.
Kristina Colle Cullin, M.D.
Scott R. Frazell, M.D.
Kristin M. Leverkus, M.D.
Robert L. Orme, M.D.
Mary J. Pare, M.D.
Don L. Ross, M.D.
W. Kent Smith, M.D.
Leonard L. Swynge, M.D.
Mark F. Taylor, M.D.
Thomas L. Davis, M.D.
Jerry D.Dickson, M.D.
Elizabeth Fulton, M.D.
Andrew D. Demos, M.D.
Jane C. Duffau, M.D.
Shalinae Dunn, M.D.
Rebecca L. Fawer, M.D.
Wayne A. Fugler, M.D.
Betheli Forbes, M.D.
Lisa A. Garnier, M.D.
James H. Haymond, Jr., M.D.
Edward R. Helfft, M.D.
Stephan D. Hoanea, M.D.
Sylvia B. Hsu, M.D.
Robert J. Pare, M.D.
WASHINGTON
Paul S. N>,</script>
The DF was designed by dermatologists, for dermatologists, specifically to help advance knowledge and patient care. Our contributions enable the Foundation—and the essential support it provides—to continue long into the future.
Financials & Governance
Financials

2017 Highlights

ASSETS, LIABILITIES, AND NET ASSETS (AS OF DECEMBER 31, 2017)

The Dermatology Foundation continues to focus on complete and accurate financial reporting in conformity with U.S. generally accepted accounting principles. Following are 2017 financial highlights of the Foundation as noted in the financial statements audited by the independent audit firm of McCollough, Rossi & Co, Ltd.

<table>
<thead>
<tr>
<th>ASSETS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current Assets:</strong></td>
<td></td>
</tr>
<tr>
<td>Cash and Equivalents</td>
<td>$3,921,831</td>
</tr>
<tr>
<td>Accounts Receivable</td>
<td>$723,250</td>
</tr>
<tr>
<td>Unconditional Promises to Give</td>
<td>$1,148,870</td>
</tr>
<tr>
<td>Investments</td>
<td>$42,000,742</td>
</tr>
<tr>
<td>Prepaid Expenses</td>
<td>$252,481</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td>$48,047,174</td>
</tr>
<tr>
<td><strong>Property and Equipment:</strong></td>
<td></td>
</tr>
<tr>
<td>Furniture and Equipment</td>
<td>$163,391</td>
</tr>
<tr>
<td>Accumulated Depreciation</td>
<td>($74,331)</td>
</tr>
<tr>
<td>Property and Equipment, Net</td>
<td>$89,060</td>
</tr>
<tr>
<td><strong>TOTAL OTHER ASSETS</strong></td>
<td>$1,046,778</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>$49,183,012</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES AND NET ASSETS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Liabilities:</strong></td>
<td></td>
</tr>
<tr>
<td>Research Award Commitment</td>
<td>$1,337,518</td>
</tr>
<tr>
<td>Accounts Payable and Accrued Expenses</td>
<td>$787,994</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td>$2,125,512</td>
</tr>
<tr>
<td><strong>Net Assets:</strong></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>$43,538,468</td>
</tr>
<tr>
<td>Temporarily Restricted</td>
<td>$3,579,032</td>
</tr>
<tr>
<td><strong>TOTAL NET ASSETS</strong></td>
<td>$47,057,500</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td>$49,183,012</td>
</tr>
</tbody>
</table>

Revenues and Expenses (As of December 31, 2017)

**UNRESTRICTED REVENUES AND GAINS**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dues</td>
<td>$2,577,761</td>
</tr>
<tr>
<td>Contributions</td>
<td>$1,368,500</td>
</tr>
<tr>
<td>Investment Income</td>
<td>$5,139,723</td>
</tr>
<tr>
<td>Other</td>
<td>$659,738</td>
</tr>
<tr>
<td><strong>TOTAL UNRESTRICTED REVENUE AND GAINS</strong></td>
<td>$9,445,722</td>
</tr>
</tbody>
</table>

**UNRESTRICTED EXPENSES**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Awards Expended, Net</td>
<td>$2,377,226</td>
</tr>
<tr>
<td>Program Services</td>
<td>$934,435</td>
</tr>
<tr>
<td>Membership Services</td>
<td>$658,420</td>
</tr>
<tr>
<td>Clinical Symposia</td>
<td>$489,144</td>
</tr>
<tr>
<td>Administrative Expenses</td>
<td>$330,761</td>
</tr>
<tr>
<td>Scientific Publications</td>
<td>$135,636</td>
</tr>
<tr>
<td>Other</td>
<td>$335,445</td>
</tr>
<tr>
<td><strong>TOTAL UNRESTRICTED EXPENSES</strong></td>
<td>$5,251,057</td>
</tr>
</tbody>
</table>

**INCREASES IN UNRESTRICTED NET ASSETS**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TEMPORARILY RESTRICTED REVENUES AND GAINS</strong></td>
<td>$4,494,665</td>
</tr>
<tr>
<td>Dues</td>
<td>$314,177</td>
</tr>
<tr>
<td>Contributions</td>
<td>$630,476</td>
</tr>
<tr>
<td><strong>TOTAL TEMPORARILY RESTRICTED REVENUES AND GAINS</strong></td>
<td>$944,653</td>
</tr>
</tbody>
</table>

**EXPENSES AND ASSETS RELEASED FROM RESTRICTIONS**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Assets Released from Restrictions</td>
<td>($1,859,250)</td>
</tr>
<tr>
<td>Increase in Temporarily Restricted Net Assets</td>
<td>($914,597)</td>
</tr>
<tr>
<td>Increase in Net Assets</td>
<td>$3,580,068</td>
</tr>
<tr>
<td>Net Assets at Beginning of Year</td>
<td>$43,477,432</td>
</tr>
<tr>
<td><strong>NET ASSETS AT END OF YEAR</strong></td>
<td>$47,057,500</td>
</tr>
</tbody>
</table>

Note: The complete audited financial statements of the Dermatology Foundation for the year ended December 31, 2017 may be obtained by contacting the Dermatology Foundation, 1560 Sherman Avenue, Suite 500, Evanston, IL 60201. The Dermatology Foundation is a 501(c)3 charitable organization. Contributions are deductible to the extent provided by law.
From very early in my career, I have valued and admired what the Dermatology Foundation does. Making sure that we stay vibrant, forward-thinking, and focused on finding answers for our patients—these are all very important to me—and to the DF.
As a member-supported nonprofit foundation, our mission depends on the vision and generosity of those who share our commitment to moving dermatology forward. On behalf of all the patients, physicians, and researchers who benefit from your support today and tomorrow: Thank you.